Melchor Gochioco, PA
Medical · Las Vegas, NVNPI 1386654788
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $54.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Abbott$1K
- Lilly USA, LLC$777
- Boehringer Ingelheim$716
- plus $4K from 23 others
What the payments were for
- Consulting fees$8007%
- Food & beverage$10,53693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $1,754 |
| Amgen(2 entities) | 36 | $1,450 |
| Biohaven Pharmaceuticals, Inc. | 4 | $1,175 |
| Abbott | 18 | $1,154 |
| Lilly USA, LLC | 32 | $777 |
| Boehringer Ingelheim | 7 | $716 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $556 |
| GSK | 6 | $443 |
| Intra-sana Laboratories | 9 | $386 |
| Johnson & Johnson | 3 | $355 |
| AbbVie | 7 | $342 |
| Novo Nordisk | 8 | $298 |
| Daiichi Sankyo Inc. | 2 | $281 |
| Lucid Diagnostics Inc. | 3 | $213 |
| Dexcom, Inc. | 7 | $206 |
| Idorsia Pharmaceuticals US Inc | 2 | $139 |
| Nevro Corp. | 1 | $138 |
| Astellas Pharma US Inc | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
| Boston Scientific | 7 | $120 |
| Gilead | 1 | $119 |
| Axsome Therapeutics, Inc. | 1 | $112 |
| EMD Serono, Inc. | 1 | $100 |
| Medline Industries LP | 1 | $43 |
| Merck | 2 | $36 |
| Genentech USA, Inc. | 1 | $22 |
| Bayer | 1 | $16 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,175
- FREESTYLE LIBRE 3$563
- Repatha$511
- FARXIGA$492
- JARDIANCE$459
- AIRSUPRA$362
- BREZTRI$358
- XARELTO$355
- Reltone 200 Mg$320
- GLYCATE$320
- Reltone 400 Mg$320
- PROCLAIM$289
- INJECTAFER$281
- QULIPTA$253
- XIFAXAN$249
- Otezla$246
- AREXVY$245
- DEXCOM G7 GSS (161)$144
- DEXCOM STELO GLUCOSE BIOSENSOR$144
- Senza$138
How this compares
$11,336 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $57,786 |
| MounjaroTirzepatide | 30 | $40,583 |
| OzempicSemaglutide | 34 | $34,105 |
| TrulicityDulaglutide | 16 | $24,649 |
| EliquisApixaban | 36 | $18,973 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $10,329 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,980 |
| Atorvastatin Calcium | 383 | $3,187 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $1,829 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,621 |
| Losartan Potassium | 160 | $1,189 |
| Gabapentin | 96 | $1,181 |
| Fluticasone Propionate | 71 | $1,006 |
| Lisinopril | 130 | $974 |
| Fenofibrate | 56 | $962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $777 | $65,23246 claims |
| Boehringer IngelheimJardiance | $716 | $57,78641 claims |
| Novo NordiskOzempic | $298 | $34,10534 claims |
| MerckJanumet | $36 | $10,32913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
- Isaac TunnellLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.